Ideaya Biosciences falls as quarterly loss widens

IDEAYA Biosciences

13/02/2025 15:36

** Shares of drug developer Ideaya Biosciences  IDYA.O  fall
4.6% to $20.94
    ** Co reports Q4 net loss of $130.3 million compared with
net loss of $34.0 million a year ago
    ** Collaboration revenue for the quarter was $7 million
compared to $3.9 million a year earlier
    ** Co received milestone payment from GSK  GSK.L  
    ** As of December 31, co had cash, cash equivalents and
marketable securities of about $1.1 billion, compared to $632.6
million a year earlier
     ** Separately, co entered into an additional clinical study
collaboration and supply agreement with Gilead Sciences  GILD.O 
to test IDYA's experimental drug, IDE397, in combination with
GILD's trodelvy to treat a type of lung cancer
    ** In the last 12 months, IDYA has fallen ~53%

 (Reporting by Siddhi Mahatole)
 ((siddhiprabhanjan.mahatole@thomsonreuters.com))